A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Amounts are shown in US dollars, translated from EUR at the rate recorded for each period. Growth rates marked (EUR) are measured in EUR, the currency the company reports in, so a move in the exchange rate does not count as growth.
Newest figures come from the 20-F for FY2025, filed Apr 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IPHA SEC filings page.
Innate Pharma S.A. (IPHA) reported $10.6M in revenue for fiscal year 2025, down 55.2% in EUR terms from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
The business remains development-stage: research spending dwarfs revenue, while cash losses are eroding the balance sheet.
In FY2025, operating cash flow of-$61.9M nearly matched free cash flow of-$62.1M , showing that the cash drain comes from core operations rather than heavy capital spending. With R&D at484.4% of revenue and capital expenditures at just1.6% , the company is funding development activity, not building a capital-intensive operating base.
Revenue fell to
FY2025 liabilities of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Innate Pharma S.A.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Innate Pharma S.A., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Innate Pharma S.A. scores 61/100 on it among other emerging companies.
Innate Pharma S.A. spent $51.2M on research and development in fiscal year 2025, which was 69.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Innate Pharma S.A. scores 88/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Innate Pharma S.A. scores 2/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Innate Pharma S.A. scores 28/100 on it among other emerging companies.
Not available for Innate Pharma S.A., so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Innate Pharma S.A. passes 0 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Innate Pharma S.A. reported a net loss of $57.7M while operations used $61.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Innate Pharma S.A. reported an operating loss of $63.4M against $516K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Innate Pharma S.A. generated $10.6M in revenue in fiscal year 2025. This represents a decrease of 55.2% in EUR terms from the prior year.
Innate Pharma S.A.'s EBITDA was -$61.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Innate Pharma S.A. reported a net loss of $57.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Innate Pharma S.A. earned -$0.65 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
Innate Pharma S.A. recorded an outflow of $62.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Innate Pharma S.A. held $33.0M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Innate Pharma S.A. invested $51.2M in research and development in fiscal year 2025. This represents a decrease of 16.1% in EUR terms from the prior year.
Innate Pharma S.A. invested $164K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 64.2% in EUR terms from the prior year.
Not reported for fiscal year 2025.
IPHA Income Statement
Figures in USD, translated from EUR at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.6M-55.2% | $20.8M-67.4% | $68.2M+6.9% | $61.7M+133.5% | $28.0M-64.6% | $85.3M-18.3% | $95.9M-9.1% | $107.6M+113.4% | $52.9M |
| R&D Expenses | $51.2M-16.1% | $53.8M-7.2% | $62.0M+8.4% | $55.3M+9.9% | $53.2M-5.4% | $60.8M-21.0% | $70.6M-9.6% | $79.7M+3.8% | $80.5M |
| Operating Income | -$63.4Mn/m | -$53.4Mn/m | -$14.0Mn/m | -$61.4Mn/m | -$54.1M-4532.3% | $1.3M-31.5% | $1.8M-69.4% | $5.9Mn/m | -$48.1M |
| EBITDA | -$61.8Mn/m | -$51.3Mn/m | -$8.4Mn/m | -$12.9Mn/m | -$48.9M-174.7% | $70.8M+219.7% | $20.3M+44.3% | $14.4Mn/m | -$42.8M |
| Interest Expense | $516K-22.3% | $586K-11.6% | $708K+122.2% | $308K-7.7% | $353K-8.5% | $417K+67.2% | $229K+100.0% | $117K-9.7% | $136K |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | -$381K-190.5% | $442K |
| Net Income | -$57.7Mn/m | -$51.2Mn/m | -$8.4Mn/m | -$62.2Mn/m | -$59.8Mn/m | -$78.3Mn/m | -$23.3M-780.8% | $3.5Mn/m | -$58.2M |
| EPS (Basic) | -$0.65n/m | -$0.63n/m | -$0.10n/m | -$0.78n/m | -$0.75n/m | -$0.99n/m | -$0.35-719.7% | $0.06n/m | -$1.07 |
| EPS (Diluted) | -$0.65n/m | -$0.63n/m | -$0.10n/m | -$0.78n/m | -$0.75n/m | -$0.99n/m | -$0.35-719.7% | $0.06n/m | -$1.07 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, Diluted Shares (Avg).
IPHA Balance Sheet
Figures in USD, translated from EUR at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $73.6M-43.5% | $115.0M-36.6% | $193.8M-12.1% | $213.2M-25.5% | $302.8M-13.0% | $376.0M-23.4% | $450.6M-11.0% | $516.9M+76.9% | $306.6M |
| Current Assets | $54.8M-45.5% | $88.8M-42.1% | $163.7M+5.9% | $149.6M+1.1% | $156.5M-20.3% | $212.1M-27.0% | $266.8M-25.7% | $366.2M+132.4% | $165.3M |
| Cash & Equivalents | $33.0M-57.7% | $68.7M-6.0% | $78.1M-16.2% | $90.1M-18.8% | $117.4M-24.2% | $167.3M-32.6% | $227.8M+33.2% | $174.5M+53.3% | $119.5M |
| Accounts Receivable | $14.6M+149.4% | $5.1M-91.1% | $61.5M+44.9% | $41.0M+108.2% | $20.8M-15.6% | $26.7M+16.4% | $21.0M-87.7% | $174.3M+610.4% | $25.7M |
| Total Liabilities | $99.1M-17.4% | $105.8M-17.1% | $136.4M-15.1% | $155.3M-9.3% | $181.2M+5.7% | $185.2M-17.7% | $206.5M-35.3% | $325.5M+82.6% | $187.0M |
| Current Liabilities | $43.0M+11.1% | $34.1M-16.8% | $43.8M-4.1% | $44.2M-48.3% | $90.4M+75.6% | $55.6M-62.7% | $136.8M-38.1% | $225.4M+166.2% | $88.9M |
| Non-Current Liabilities | $56.1M-31.0% | $71.7M-17.2% | $92.5M-19.4% | $111.1M+29.5% | $90.7M-24.3% | $129.6M+70.6% | $69.7M-28.8% | $99.9M-8.3% | $114.4M |
| Total Equity | -$25.5M-345.7% | $9.1M-83.0% | $57.4M-4.2% | $57.9M-49.6% | $121.6M-31.1% | $190.8M-28.3% | $244.1M+30.1% | $191.5M+68.1% | $119.6M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | -$151.5Mn/m | -$159.2Mn/m | -$124.5M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.
IPHA Cash Flow Statement
Figures in USD, translated from EUR at the rate recorded for each period, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$61.9Mn/m | -$7.1Mn/m | -$36.0Mn/m | -$20.5Mn/m | -$66.2Mn/m | -$63.3M-248.2% | $39.2Mn/m | -$37.3Mn/m | -$57.8M |
| Depreciation & Amortization | $1.6M-30.6% | $2.1M-60.8% | $5.6M-88.8% | $48.6M+887.9% | $5.2M-91.9% | $69.5M+243.6% | $18.6M+123.3% | $8.5M+68.5% | $5.3M |
| Capital Expenditures | $164K-64.2% | $405K+11.4% | $388K-34.4% | $572K-42.4% | $1.1M+2.4% | $1.1M-28.6% | $1.4M+45.6% | $1.0M-70.5% | $3.6M |
| Free Cash Flow | -$62.1Mn/m | -$7.5Mn/m | -$36.4Mn/m | -$21.1Mn/m | -$67.2Mn/m | -$64.4M-256.5% | $37.8Mn/m | -$38.3Mn/m | -$61.3M |
| Investing Cash Flow | $8.6M-20.8% | $9.5M-55.4% | $22.8M+999.1% | $2.0Mn/m | -$1.0Mn/m | -$16.4Mn/m | -$69.7M-355.9% | $27.8Mn/m | -$35.4M |
| Financing Cash Flow | $7.1Mn/m | -$6.2Mn/m | -$2.2Mn/m | -$2.0M-106.8% | $30.4Mn/m | -$1.4M-101.5% | $87.3M+27.0% | $70.1M+6590.9% | $1.1M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
IPHA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -599.8% | -256.3% | -20.5%+79.0pp | -99.6% | -193.6% | 1.6%-0.3pp | 1.8%-3.6pp | 5.5%+96.3pp | -90.8% |
| Net Margin | -546.1% | -245.9% | -12.3% | -100.7% | -213.8% | -91.7%-67.4pp | -24.3%-27.5pp | 3.3% | -109.9% |
| Return on Equity | N/A | -560.0%-545.4pp | -14.6%+92.7pp | -107.3%-58.1pp | -49.1%-8.1pp | -41.0%-31.5pp | -9.6%-11.4pp | 1.8%+50.5pp | -48.7% |
| Return on Assets | -78.4%-33.9pp | -44.5%-40.2pp | -4.3%+24.8pp | -29.1%-9.4pp | -19.7%+1.1pp | -20.8%-15.6pp | -5.2%-5.9pp | 0.7%+19.7pp | -19.0% |
| Current Ratio | 1.27-1.3x | 2.60-1.1x | 3.73+0.4x | 3.38+1.7x | 1.73-2.1x | 3.81+1.9x | 1.95+0.3x | 1.62-0.2x | 1.86 |
| Liabilities-to-Equity | N/A | 11.57+9.2x | 2.38-0.3x | 2.68+1.2x | 1.49+0.5x | 0.97+0.1x | 0.85-0.9x | 1.70+0.1x | 1.56 |
| Asset Turnover | 0.140.0x | 0.18-0.2x | 0.35+0.1x | 0.29+0.2x | 0.09-0.1x | 0.230.0x | 0.210.0x | 0.210.0x | 0.17 |
| FCF Margin | -587.4% | -36.2%+17.2pp | -53.4%-19.3pp | -34.1% | -240.4% | -75.5%-114.9pp | 39.4%+74.9pp | -35.5% | -115.9% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$25.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Innate Pharma S.A. IPHA | FY2025 | $10.6M | -$57.7M | N/A | $105.0M | 45/100 |
| Sutro Biopharma, Inc. STRO | FY2025 | $102.5M | -$191.1M | N/A | $144.8M | 42/100 |
| enGene Therapeutics Inc. ENGN | FY2025 | N/A | -$117.3M | N/A | $117.9M | — |
| MacroGenics, Inc. MGNX | FY2025 | $149.5M | -$74.6M | -49.9% | $126.5M | 59/100 |
| Compass Therapeutics, Inc. CMPX | FY2025 | $0 | -$66.5M | N/A | $122.2M | — |
| Zentalis Pharmaceuticals, Inc. ZNTL | FY2025 | $0 | -$137.1M | N/A | $133.6M | — |
Where Innate Pharma S.A. Ranks
Frequently Asked Questions
Innate Pharma S.A. (IPHA) reported $10.6M in total revenue for fiscal year 2025. This represents a -55.2% change in EUR terms compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Innate Pharma S.A. (IPHA) revenue declined by 55.2% year-over-year in EUR, the currency it reports in. Translated at each year’s own exchange rate, it went from $20.8M to $10.6M in fiscal year 2025.
No, Innate Pharma S.A. (IPHA) reported a net loss of $57.7M in fiscal year 2025.
Innate Pharma S.A. (IPHA) had EBITDA of -$61.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Innate Pharma S.A. (IPHA) recorded an outflow of $62.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Innate Pharma S.A. (IPHA) recorded an outflow of $61.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Innate Pharma S.A. (IPHA) had $73.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Innate Pharma S.A. (IPHA) invested $164K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Innate Pharma S.A. (IPHA) invested $51.2M in research and development during fiscal year 2025.
Innate Pharma S.A. (IPHA) had a current ratio of 1.27 as of fiscal year 2025, which is considered adequate.
Innate Pharma S.A. (IPHA) had a return on assets of -78.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Innate Pharma S.A. (IPHA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $105.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Innate Pharma S.A. (IPHA) trades at 9.9x sales, its market capitalization divided by $10.6M revenue, FY2025. The market capitalization is $105.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Innate Pharma S.A. (IPHA) has negative shareholder equity of -$25.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Innate Pharma S.A. (IPHA) has a Piotroski F-Score of 0 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Innate Pharma S.A. (IPHA) reported a net loss of $57.7M while operations used $61.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Innate Pharma S.A. (IPHA) reported an operating loss of $63.4M against $516K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Innate Pharma S.A. (IPHA) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Innate Pharma S.A. it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.